Jury Awards Ariad $65.2M In Lilly Patent Feud

Law360, New York (May 4, 2006, 12:00 AM EDT) -- In the latest development in a long-running legal battle, a federal jury has awarded at least $65.2 million to Ariad Pharmaceuticals Inc. after finding that Eli Lilly and Co.’s osteoporosis drug Evista and septic shock drug Xigris infringed on an Ariad patent.

The patent at issue in the case, U.S. Patent No. 6,410,516, is owned by the Massachusetts Institute of Technology, the Whitehead Institute for Biomedical Research and the President and Fellows of Harvard College, and is licensed to Ariad.

Kineret is used to treat pain...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.